VCAM-1 (Vascular Cell Adhesion Molecule-1) Gene Expression Inhibitor - Pipeline Insight, 2019 - ResearchAndMarkets.com

The "VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, January 22, 2019
Information
Tags: 
Health, Genetics, Proteins, Branches of biology, SIGLEC, VCAM-1, Membrane proteins, Cell adhesion, Protein domains, Transmembrane receptors, Single-pass transmembrane proteins, IgSF CAM, Zaurategrast
⚠generated by AI ↴
Summary
Key Points: 
  • The "VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • The report assesses the active VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.


The "VCAM-1
(vascular cell adhesion molecule-1) gene expression inhibitor -Pipeline
Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's
offering.

This report offers comprehensive insights of the pipeline (under
development) therapeutics scenario and growth prospects across VCAM-1
(vascular cell adhesion molecule-1) gene expression inhibitor
development.

The report provides detailed coverage of the pipeline landscape for this
mechanism of action, equipped with data from multiple sources with
complete pipeline analysis by developmental stage, associated
indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental
Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product
profiles including (but not limited to) drug description, product
development and R&D activities encompassing clinical and pre-clinical
studies, designations, collaborations, licensing deals, grants,
technologies and patent details.

The report assesses the active VCAM-1 (vascular cell adhesion
molecule-1) gene expression inhibitor pipeline products by developmental
stage, product type, molecule type, and administration route.

Companies Featured

  • Encysive Pharmaceuticals
  • AtheroGenics

Topics Covered

1. Report Introduction

2. VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor
- Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor
Pipeline Products in Clinical Stages

6. VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor
Pipeline Products in Non-clinical Stages

7. Therapeutic Assessment - Active Products

8. Inactive Pipeline Products

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/h2s53k/vcam1_vascular?w=4

Copyright: 
Copyright Business Wire 2019